Trials / Suspended
SuspendedNCT03659669
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Post Marketing Observational Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
- Status
- Suspended
- Phase
- —
- Study type
- Observational
- Enrollment
- 272 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
Conditions
Timeline
- Start date
- 2019-02-10
- Primary completion
- 2027-02-28
- Completion
- 2027-02-28
- First posted
- 2018-09-06
- Last updated
- 2023-10-23
Locations
13 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT03659669. Inclusion in this directory is not an endorsement.